| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 12/10/2013 | CA2464700C Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer |
| 12/10/2013 | CA2453173C Mycobacterial antigens expressed during latency |
| 12/10/2013 | CA2451026C Mycobacterial antigens expressed under low oxygen tension |
| 12/10/2013 | CA2443617C Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| 12/10/2013 | CA2385528C Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 12/10/2013 | CA2385032C G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 12/10/2013 | CA2341349C Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof |
| 12/05/2013 | WO2013181634A2 Antigen binding proteins that bind pd-l1 |
| 12/05/2013 | WO2013181612A1 High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia |
| 12/05/2013 | WO2013181543A1 High-affinity monoclonal antibodies to glypican-3 and use thereof |
| 12/05/2013 | WO2013181452A1 Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| 12/05/2013 | WO2013181253A1 Production cell line enhancers |
| 12/05/2013 | WO2013181087A2 Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
| 12/05/2013 | WO2013180834A2 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
| 12/05/2013 | WO2013180648A1 Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations |
| 12/05/2013 | WO2013180647A1 Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities |
| 12/05/2013 | WO2013180473A1 Bicistronic expression vector for expressing antibody and method for producing antibody using the same |
| 12/05/2013 | WO2013180238A1 Therapeutic agent or prophylactic agent for dementia |
| 12/05/2013 | WO2013180201A1 Antigen-binding molecule for eliminating aggregated antigens |
| 12/05/2013 | WO2013180200A1 Target-tissue-specific antigen-binding molecule |
| 12/05/2013 | WO2013179143A2 Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors |
| 12/05/2013 | WO2013178783A1 P2x7 receptor antagonists and agonists |
| 12/05/2013 | WO2013178736A1 Tlr3 binding agents |
| 12/05/2013 | WO2013178707A1 Diagnostic method for determining the presence and amount of human interleukin-3 in a sample using novel il-3 antibodies |
| 12/05/2013 | WO2013178706A1 Novel il-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of il-3 |
| 12/05/2013 | WO2013178236A1 Carbohydrate-glycolipid conjugate vaccines |
| 12/05/2013 | WO2013154458A3 Monomolecular chimeric t-cell receptor to a carcinoembryonic antigen |
| 12/05/2013 | WO2013152351A3 Fusion polypeptides and methods of use thereof |
| 12/05/2013 | WO2013130826A3 Igg stimulated remyelination of peripheral nerves |
| 12/05/2013 | WO2013123114A3 Anti-vla1 (cd49a) antibody pharmaceutical compositions |
| 12/05/2013 | WO2013064700A3 Chimeric human-camel antigens and their use |
| 12/05/2013 | US20130324705 Lox and loxl2 inhibitors and uses thereof |
| 12/05/2013 | US20130324704 Humanized anti-egfl7 antibodies and methods using same |
| 12/05/2013 | US20130324703 Antibody therapy for use in the digestive tract |
| 12/05/2013 | US20130324701 Compositions and methods of treating disease with fgfr fusion proteins |
| 12/05/2013 | US20130324698 Anti-syndecan-4 antibodies |
| 12/05/2013 | US20130323791 Restricted immunoglobulin heavy chain mice |
| 12/05/2013 | US20130323790 Human lambda light chain mice |
| 12/05/2013 | US20130323789 Anti system asc amino acid transporter 2 (asct2) antibody |
| 12/05/2013 | US20130323788 Production cell line enhancers |
| 12/05/2013 | US20130323786 Composition Comprising Antibodies to LINGO or Fragments Thereof |
| 12/05/2013 | US20130323759 Spinal muscular atrophy diagnostic methods |
| 12/05/2013 | US20130323747 Targeting and tracing of antigens in living cells |
| 12/05/2013 | US20130323717 Repeat-chain for the production of dimer, multimer, multimer complex and super-complex |
| 12/05/2013 | US20130323300 Therapeutic composition for treatment of glioblastoma |
| 12/05/2013 | US20130323262 Methods and materials for treating inflammatory conditions |
| 12/05/2013 | US20130323259 Il-21 ligands |
| 12/05/2013 | US20130323258 Compositions and methods for treating cardivascular disease |
| 12/05/2013 | US20130323257 Antibodies that bind the glutamate ligand binding region of notch3 |
| 12/05/2013 | US20130323256 S. agalactiae antigens i + ii |
| 12/05/2013 | US20130323255 Serum mg53 as a diagnostic marker for tissue injury |
| 12/05/2013 | US20130323254 Therapeutic anti-tirc7 antibodies for use in immune related and other diseases |
| 12/05/2013 | US20130323252 Molecules And Methods For Modulating TMEM16A Activities |
| 12/05/2013 | US20130323250 Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes |
| 12/05/2013 | US20130323249 Antigen Binding Proteins that Bind PD-L1 |
| 12/05/2013 | US20130323248 Antigen Binding Proteins that Bind DLL-4 |
| 12/05/2013 | US20130323247 Treatment of acute lymphoblastic leukemia |
| 12/05/2013 | US20130323245 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| 12/05/2013 | US20130323241 Treatment of angiogenesis disorders |
| 12/05/2013 | US20130323240 Humanized antibodies against light and uses thereof |
| 12/05/2013 | US20130323238 Antagonists of il-6 to raise albumin and/or lower crip |
| 12/05/2013 | US20130323237 Organic compounds |
| 12/05/2013 | US20130323236 Antibodies of the Class IGG4 |
| 12/05/2013 | US20130323235 Soluble heavy-chain only antibodies |
| 12/05/2013 | US20130323234 Mutant antibodies and conjugation thereof |
| 12/05/2013 | US20130323233 Materials and methods for improved immunoglycoproteins |
| 12/05/2013 | US20130323204 Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy |
| 12/05/2013 | US20130323173 Antibodies to tumor endothelial marker 8 |
| 12/05/2013 | DE102012102998B4 New polymer comprising two substances that bind to amyloid-beta-oligomers, useful for treating Alzheimer's disease, Parkinson's disease, Creutzfeldt Jakob disease or diabetes |
| 12/05/2013 | CA2875234A1 P2x7 receptor antagonists and agonists |
| 12/05/2013 | CA2875205A1 Therapeutic agent or prophylactic agent for dementia |
| 12/05/2013 | CA2875137A1 High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia |
| 12/05/2013 | CA2874918A1 Tlr3 binding agents |
| 12/04/2013 | EP2669375A1 Yeast for transformation and process for producing protein |
| 12/04/2013 | EP2669298A2 Single variable immunoglobulin domain comprising VL-DH-JL |
| 12/04/2013 | EP2669297A1 Humanized anti-egfr antibody l4-h3 and coding gene thereof |
| 12/04/2013 | EP2669296A1 Anti-il28b antibody and method for assaying il28b using same |
| 12/04/2013 | EP2669295A1 Diagnostic method for determining the presence and amount of human interleukin-3 in a sample using novel IL-3 antibodies |
| 12/04/2013 | EP2669294A1 Novel IL-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of IL-3 |
| 12/04/2013 | EP2668498A2 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto |
| 12/04/2013 | EP2668212A2 Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| 12/04/2013 | EP2668211A1 Pharmaceutical compositions comprising human antibodies to pcsk9 |
| 12/04/2013 | EP2668210A2 Anti-kit antibodies and uses thereof |
| 12/04/2013 | EP2668209A1 Antibodies selective for cells presenting egfr at high density |
| 12/04/2013 | EP2668208A1 Cross-reactive staphylococcus aureus antibody |
| 12/04/2013 | EP2668207A1 Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
| 12/04/2013 | EP2668206A1 Engineering of immunoglobulin domains |
| 12/04/2013 | EP2667895A1 Use of at least one p75ntr receptor inhibitor, alone or in association with at least one trka receptor activator, or of at least one trka receptor activator, for the treatment of chronic inflammatory diseases |
| 12/04/2013 | CN103429746A ADAM6 mice |
| 12/04/2013 | CN103429737A Cytotoxicity-inducing therapeutic agent |
| 12/04/2013 | CN103429620A Stable heterodimeric antibody design with mutations in the Fc domain |
| 12/04/2013 | CN103429619A Bi- and monospecific, asymmetric antibodies and method of generating same |
| 12/04/2013 | CN103429618A Antibodies against ROR1 and uses thereof |
| 12/04/2013 | CN103429617A A marker comprising anti-CK8/18 complex autoantibody and its use for diagnosing cancer |
| 12/04/2013 | CN103429616A Antibodies binding human collagen II |
| 12/04/2013 | CN103429615A Means and methods for producing high affinity antibodies |
| 12/04/2013 | CN103429262A Overcoming resistance to ERBB pathway inhibitors |
| 12/04/2013 | CN103429261A Modified antibody with improved half-life |
| 12/04/2013 | CN103421832A Preparation and application of egg yolk antibody containing florfenicol drug resistance gene protein |
| 12/04/2013 | CN103421747A Hybridoma cell strain capable of secreting bovine IL-4 monoclonal antibody, monoclonal antibody secreted by hybridoma cell strain and application of hybridoma cell strain |